The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Incyte; Medscape; Merck; MSD; Pfizer; Roche; Roche/Genentech; UroToday
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Karim Fizazi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac (Inst); ESSA (Inst); Janssen Oncology; Orion; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen
 
Bertrand F. TOMBAL
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Janssen
Research Funding - Ferring (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Christian Wülfing
No Relationships to Disclose
 
Gero Kramer
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Novartis; Sanofi; Takeda
Research Funding - Bayer (Inst); Sanofi (Inst)
 
Jean-Christophe Eymard
Leadership - Sanofi
Honoraria - Sanofi
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Joan Carles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Asofarma; Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi/Aventis (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZéneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Roche (Inst)
 
Roberto Iacovelli
Honoraria - Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Sanofi
 
Bohuslav Melichar
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; SERVIER
 
Asgerdur Sverrisdottir
No Relationships to Disclose
 
Christine Theodore
No Relationships to Disclose
 
Susan Feyerabend
No Relationships to Disclose
 
Carole Helissey
No Relationships to Disclose
 
Elizabeth Poole
Employment - Sanofi
 
Ayse Ozatilgan
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Christine Geffriaud-Ricouard
Employment - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Ronald De Wit
Honoraria - Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Janssen; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly